Oral Pomegranate Extract on the Microbiome and Skin Biophysical Properties
NCT ID: NCT04596722
Last Updated: 2021-04-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
18 participants
INTERVENTIONAL
2020-11-09
2021-03-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Therefore, the aim of this study is to assess how Pomella alters the gut microbiome and the blood level of short chain fatty acids in healthy subjects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pomegranate Products for Prevention of Common Cold
NCT00617318
A Clinical Study on the Improvement of Skin and Living Conditions After Drinking Rosa Roxburghii and Pomegranate Drinks
NCT06274450
China Cimicifuga Trial of Climacteric Complaint Control
NCT00622986
The Effects of Terminalia Chebula Fruit Extract on the Gut Microbiome and Skin Biophysical Properties
NCT04597502
Effects of Monarda Didyma Extract Supplementation on Biological Ageing
NCT05399966
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Assigned Interventions
oral active pomella taken by mouth once per day
Pomella
Pomella® Pomegranate Whole Fruit Extract containing 75 mg punicalagin in white/white HPMC size "1" capsules packed in white color HDPE bottle of 30 counts
Placebo
oral placebo taken by mouth once per day
Placebo
White/white HPMC size "1" capsules each containing 97.67% Maltodextrin, 0.10% Tartrazine color, 0.22% Brown Color, 2.01% Aerosil packed in white color HDPE bottle of 30 counts
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pomella
Pomella® Pomegranate Whole Fruit Extract containing 75 mg punicalagin in white/white HPMC size "1" capsules packed in white color HDPE bottle of 30 counts
Placebo
White/white HPMC size "1" capsules each containing 97.67% Maltodextrin, 0.10% Tartrazine color, 0.22% Brown Color, 2.01% Aerosil packed in white color HDPE bottle of 30 counts
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Must be willing to comply with all protocol requirements
3. Must be willing to have flash photo facial images taken with the imaging systems
4. Males must be willing to shave any facial hair
Exclusion Criteria
2. Any topical antibiotic or benzoyl peroxide within 1 month of starting study or any subject unwilling to refrain from washout of topical antibacterial or benzoyl peroxide ingredient.
3. No intake of alcohol or tea throughout the duration of the study.
4. No more than 1 8 oz cup of coffee per week throughout the duration of the study.
5. No more than 1 cup of berries (strawberries, blueberries, raspberries, blackberries, etc.) per week throughout the duration of the study.
6. No intake of pomegranate, or pomegranate-containing drinks throughout the duration of the study.
7. No intake of chocolate (in any form) throughout the duration of the study.
8. No more than 1 cup of fermented dairy products per week throughout the duration of the study.
9. Any oral probiotic or prebiotic supplementation within past 1 month
10. Subjects must have no history of malignancy or cancer or diagnosis of gastrointestinal inflammatory diseases, no history or diagnosis of epilepsy, no history or diagnosis of immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus, rheumatoid arthritis)
11. Has a condition or is on medication the investigator and/or designee believe could jeopardize the safety of the subject, interfere with the evaluation, or confound the interpretation of the study results
12. Women who have been pregnant in the last three months, are pregnant, preparing to be pregnant or lactating.
13. Is participating in a concurrent clinical research study or has participated in an acne or other facial study at this or any other facility in the past 4 weeks
14. Those with BMI higher than 35 kg/m²
15. Commencement of a new diet (such as the ketogenic diet) or supplements within the 1 month prior to initiating participation, at the discretion of the investigator.
16. Use of medications that alter blood lipids, such as statins and anti-hyperlipidemic medications
17. Is participating in or has participated in a facial study at this or any other facility in the past 4 weeks. Participation in survey-based studies are approved at the discretion of the investigator.
18. Has a skin disease on face that will interfere with image collection and assessment in the opinion of the investigator
19. Refusal to shave or remove facial hair that may interfere with image collection and assessment.
20. Persons unwilling to avoid the following during the 4 weeks prior and during the duration of the study: self-tanning, spa tanning, sun tanning, or artificial tanning.
21. Planned vacation to sunny destination with the intention of sun tanning during the duration of the study.
22. Persons who regularly undergo sauna treatments (dry or wet) or who swim daily.
23. Known allergy or irritation to the supplement or facial products utilized in the study
24. Current tobacco smokers, OR those that have smoked tobacco over the past year, OR a 5 year-pack year history of smoking tobacco
25. Prisoners
26. Adults unable to consent
27. Vegans
25 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Verdure Sciences
INDUSTRY
Integrative Skin Science and Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Integrative Skin Science and Research
Sacramento, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
POM01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.